|

Duvelisib Clinical Trials

4 actively recruiting trials across 3 locations

Pipeline

Phase 1: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Memorial Sloan Kettering Cancer Center2
  • SecuraBio1
  • Jonsson Comprehensive Cancer Center1

Indications

  • Cancer4
  • T-cell Prolymphocytic Leukemia2
  • NK-Cell Lymphomas1
  • T-cell Lymphomas1
  • Cutaneous T-Cell Lymphoma Refractory1

Other1 trial

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Phase 3

Los Angeles, California1 trial

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

David Geffen School of Medicine at the University of California at Los Angeles

Phase 1/2

Miami, Florida1 trial

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

University of Miami (Data Collection Only)

Phase 1

Basking Ridge, New Jersey1 trial

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Memorial Sloan Kettering Basking Ridge (LimitedProtocol Activities)

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.